Literature DB >> 28429075

Toward personalized management in bladder cancer: the promise of novel molecular taxonomy.

Marie-Lisa Eich1, Lars Dyrskjøt2, George J Netto3.   

Abstract

Empowered by the recent advances in next generation sequencing and bioinformatics technology, an unprecedented wave of integrated transcriptomic and genomic studies have impacted the field of bladder cancer. These studies not only have confirmed previously charted genetic pathways in bladder cancer development but also have led to the discovery of numerous additional crucial driver genetic alterations. As a result, a novel genomic-based taxonomy is emerging that promises to better define clinically relevant intrinsic subtypes of bladder cancer. The current review is an update on the above advances and their significant implications on the future of bladder cancer patient management.

Entities:  

Keywords:  Bladder cancer; Genomics; Personalized medicine

Mesh:

Substances:

Year:  2017        PMID: 28429075     DOI: 10.1007/s00428-017-2119-x

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  78 in total

Review 1.  Molecular substratification of bladder cancer: moving towards individualized patient management.

Authors:  Anirban P Mitra
Journal:  Ther Adv Urol       Date:  2016-03-28

2.  Role for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma.

Authors:  George J Netto
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

3.  Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer.

Authors:  Mona Fahmy; Jose Joao Mansure; Fadi Brimo; Faysal A Yafi; Robert Segal; Abdulaziz Althunayan; Jessica Hicks; Alan Meeker; George Netto; Wassim Kassouf
Journal:  Hum Pathol       Date:  2013-04-23       Impact factor: 3.466

4.  Molecular evolution of multiple recurrent cancers of the bladder.

Authors:  A A van Tilborg; A de Vries; M de Bont; L E Groenfeld; T H van der Kwast; E C Zwarthoff
Journal:  Hum Mol Genet       Date:  2000-12-12       Impact factor: 6.150

5.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

Review 6.  Emerging Bladder Cancer Biomarkers and Targets of Therapy.

Authors:  George J Netto; Laura J Tafe
Journal:  Urol Clin North Am       Date:  2016-02       Impact factor: 2.241

Review 7.  Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.

Authors:  Sebastien Antoni; Jacques Ferlay; Isabelle Soerjomataram; Ariana Znaor; Ahmedin Jemal; Freddie Bray
Journal:  Eur Urol       Date:  2016-06-28       Impact factor: 20.096

8.  Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.

Authors:  Sunanda J Chatterjee; Ram Datar; David Youssefzadeh; Ben George; Peter J Goebell; John P Stein; Lillian Young; Shan-Rong Shi; Conway Gee; Susan Groshen; Donald G Skinner; Richard J Cote
Journal:  J Clin Oncol       Date:  2004-02-23       Impact factor: 44.544

9.  A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.

Authors:  C-C Lin; W-C Su; C-J Yen; C-H Hsu; W-P Su; K-H Yeh; Y-S Lu; A-L Cheng; D C-L Huang; H Fritsch; F Voss; T Taube; J C-H Yang
Journal:  Br J Cancer       Date:  2014-04-22       Impact factor: 7.640

10.  Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting.

Authors:  Seth P Lerner; David J McConkey; Katherine A Hoadley; Keith S Chan; William Y Kim; François Radvanyi; Mattias Höglund; Francisco X Real
Journal:  Bladder Cancer       Date:  2016-01-07
View more
  7 in total

1.  Research Progress of Urine Biomarkers in the Diagnosis, Treatment, and Prognosis of Bladder Cancer.

Authors:  Feng Jin; Muhammad Shahid; Jayoung Kim
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  The importance of personalized medicine in urological cancers.

Authors:  Fatemeh Khatami; Mandana Hassanzad; Shekoufeh Nikfar; Fateme Guitynavard; Samira Karimaee; Saeyed Saeed Tamehri Zadeh; Keykavos Gholami; AhmadReza Rezaeian; Seyed Ariana Feiz-Abadi; Fatemeh Jahanshahi; Seyed Mohammad Kazem Aghamir
Journal:  J Diabetes Metab Disord       Date:  2021-06-29

3.  Increased expression of EZH2 indicates aggressive potential of urothelial carcinoma of the bladder in a Chinese population.

Authors:  Xiaozhou Zhou; Nan Liu; Jingqi Zhang; Huixiang Ji; Yuting Liu; Jin Yang; Zhiwen Chen
Journal:  Sci Rep       Date:  2018-12-12       Impact factor: 4.379

Review 4.  REVIEW OF THE BLADDER CANCER MOLECULAR CLASSIFICATION PROPOSED: A NEW ERA - NEW TAXONOMY.

Authors:  Šoip Šoipi; Majda Vučić; Borislav Spajić; Božo Krušlin; Miroslav Tomić; Monika Ulamec
Journal:  Acta Clin Croat       Date:  2022-02       Impact factor: 0.780

Review 5.  Bladder Cancer: New Insights into Its Molecular Pathology.

Authors:  Kentaro Inamura
Journal:  Cancers (Basel)       Date:  2018-04-01       Impact factor: 6.639

6.  Overexpression of high mobility group box 1 contributes to progressive clinicopathological features and poor prognosis of human bladder urothelial carcinoma.

Authors:  Changkun Huang; Zhichao Huang; Xiaokun Zhao; Yinhuai Wang; Hongqing Zhao; Zhaohui Zhong; Lang Wang
Journal:  Onco Targets Ther       Date:  2018-04-12       Impact factor: 4.147

7.  Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer.

Authors:  Tim Muilwijk; Murat Akand; Frank Van der Aa; Vincent De Coninck; Marc Claessens; Robert Hente; Markus Eckstein; Yves Allory; Louis Libbrecht; Steven Joniau; Thomas Gevaert
Journal:  J Cell Mol Med       Date:  2021-06-29       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.